Expanding horizons: lung transplantation for non-IPF interstitial lung diseases

Area of Science:

• Pulmonology
• Transplant Surgery
• Critical Care Medicine

Background:

• Interstitial lung diseases (ILDs) encompass diverse pulmonary disorders characterized by inflammation and fibrosis.
• Variability in ILD presentation and treatment complicates diagnosis and management.
• Lung transplantation for advanced ILDs presents challenges in patient selection and indication determination.

Purpose of the Study:

• To analyze clinical data and survival outcomes of patients with non-idiopathic pulmonary fibrosis (non-IPF) ILD.
• To compare outcomes between patients who underwent lung transplantation and those who died awaiting transplantation.
• To evaluate the efficacy of lung transplantation as a treatment for advanced non-IPF ILDs.

Main Methods:

• Retrospective analysis of patients with non-IPF ILD from December 2016 to December 2022.
• Categorization of patients into transplanted and deceased waiting list groups.
• Comparison of clinical characteristics, including demographics, 6-minute walk test (6MWT), forced vital capacity (FVC), and pulmonary hypertension (PH), and survival outcomes.

Main Results:

• Of 43 patients, 20 received lung transplants, and 23 died on the waiting list, resulting in a 53.4% waiting list mortality.
• No significant differences were observed in baseline characteristics (age, gender, BMI, 6MWT, FVC) between the groups.
• Lung transplantation showed a 1-year survival rate of 65% (13/20 survived to discharge), with conditional survival rates of 90.9% at 3 years and 70.7% at 5 years.

Conclusions:

• Lung transplantation is a crucial intervention for select patients with advanced non-IPF ILDs.
• Further research is essential to optimize management and outcomes for non-IPF ILDs.
• Transplantation can significantly improve both quality of life and longevity in patients with advanced ILD.